Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Causes & Control
Published in: Cancer Causes & Control 3/2011

01-03-2011 | Original paper

Helicobacter pylori infection and gastric cardia cancer: systematic review and meta-analysis

Authors: Marlene Cavaleiro-Pinto, Bárbara Peleteiro, Nuno Lunet, Henrique Barros

Published in: Cancer Causes & Control | Issue 3/2011

Login to get access

Abstract

Objective

Helicobacter pylori infection is the most important risk factor for gastric cancer, but no association with cardia cancer has been recognized. However, a heterogeneous distribution of etiologically distinct types of cardia cancer may contribute to explain conflicting findings between studies in high- and low-risk settings. We aimed to quantify the association between H. pylori infection and gastric cardia cancer through meta-analysis, and to provide an explanation for the expected heterogeneity of results.

Methods

We systematically reviewed published studies addressing the association between H. pylori infection and gastric cardia cancer (up to June 2009), and extracted relative risk (RR) estimates for the association with cardia and non-cardia cancers. Summary RR estimates and 95% confidence intervals (95% CI) were computed using random-effects models. Subgroup analyses were conducted, namely according to gastric cancer risk settings.

Results

Thirty-four articles were considered for meta-analysis. For cardia cancer, summary RR was 1.08 (95% CI 0.83–1.40; I 2 = 52.8%), higher in high-risk (RR = 1.98; 95% CI 1.38–2.83; I 2 = 18.4%) than in low-risk settings (RR = 0.78; 95% CI 0.63–0.97; I 2 = 11.6%). For non-cardia cancer, RR estimates were similar in high- (RR = 3.02; 95% CI 1.92–4.74; I 2 = 90.7%) and low-risk settings (RR = 2.56; 95% CI 1.99–3.29; I 2 = 46.6%). These observations were consistent across different inclusion criteria and when accounting for the virulence of the infecting strains.

Conclusions

In high-risk settings, a positive association between H. pylori infection and gastric cancer was observed both for cardia and non-cardia cancers. The results support the hypothesis of a heterogeneous distribution of etiologically distinct types of cardia cancer.
Appendix
Available only for authorised users
Literature
1.
Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas BD (2002) Cancer incidence in five continents. IARC Sci Publ No. 155. IARC, Lyon
2.
Armstrong RW, Borman B (1996) Trends in incidence rates of adenocarcinoma of the oesophagus and gastric cardia in New Zealand, 1978–1992. Int J Epidemiol 25:941–947CrossRefPubMed
3.
Bertuccio P, Chatenoud L, Levi F et al (2009) Recent patterns in gastric cancer: a global overview. Int J Cancer 125:666–673CrossRefPubMed
4.
Hansen S, Wiig JN, Giercksky KE, Tretli S (1997) Esophageal and gastric carcinoma in Norway 1958–1992: incidence time trend variability according to morphological subtypes and organ subsites. Int J Cancer 71:340–344CrossRefPubMed
5.
Pera M, Cameron AJ, Trastek VF, Carpenter HA, Zinsmeister AR (1993) Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology 104:510–513PubMed
6.
Moller H (1992) Incidence of cancer of oesophagus, cardia and stomach in Denmark. Eur J Cancer Prev 1:159–164CrossRefPubMed
7.
Harrison SL, Goldacre MJ, Seagroatt V (1992) Trends in registered incidence of oesophageal and stomach cancer in the Oxford region, 1974–88. Eur J Cancer Prev 1:271–274CrossRefPubMed
8.
Levi F, La Vecchia C, Te VC (1990) Descriptive epidemiology of adenocarcinomas of the cardia and distal stomach in the Swiss Canton of Vaud. Tumori 76:167–171PubMed
9.
Thomas RJ, Lade S, Giles GG, Thursfield V (1996) Incidence trends in oesophageal and proximal gastric carcinoma in Victoria. Aust N Z J Surg 66:271–275CrossRefPubMed
10.
Correa P, Haenszel W, Cuello C, Tannenbaum S, Archer M (1975) A model for gastric cancer epidemiology. Lancet 2:58–60CrossRefPubMed
11.
Popiela T, Kulig J, Kolodziejczyk P, Sierzega M (2002) Changing patterns of gastric carcinoma over the past two decades in a single institution: clinicopathological findings in 1557 patients. Scand J Gastroenterol 37:561–567CrossRefPubMed
12.
Lee JY, Kim HY, Kim KH et al (2003) No changing trends in incidence of gastric cardia cancer in Korea. J Korean Med Sci 18:53–57PubMed
13.
Blot WJ, Devesa SS, Kneller RW, Fraumeni JF Jr (1991) Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 265:1287–1289CrossRefPubMed
14.
Bouvier AM, Esteve J, Mitry E, Clinard F, Bonithon-Kopp C, Faivre J (2002) Trends in gastric cancer incidence in a well-defined French population by time period and birth cohort. Eur J Cancer Prev 11:221–227CrossRefPubMed
15.
Crane SJ, Richard Locke G III, Harmsen WS et al (2007) The changing incidence of oesophageal and gastric adenocarcinoma by anatomic sub-site. Aliment Pharmacol Ther 25:447–453CrossRefPubMed
16.
Huang JQ, Hunt RH (2003) The evolving epidemiology of Helicobacter pylori infection and gastric cancer. Can J Gastroenterol 17(Suppl B):18B–20BPubMed
17.
Eslick GD, Lim LL, Byles JE, Xia HH, Talley NJ (1999) Association of Helicobacter pylori infection with gastric carcinoma: a meta-analysis. Am J Gastroenterol 94:2373–2379CrossRefPubMed
18.
Huang JQ, Sridhar S, Chen Y, Hunt RH (1998) Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology 114:1169–1179CrossRefPubMed
19.
Webb PM, Law M, Varghese C, Forman D, Yuan JM, Yu M, Ross R, Limberg PJ, Mark SD, Taylor PR, Dawsey SM, Qiao YL, Aromaa A, Knekt P, Kosunen TU, Heinonen OP, Virtamo J, Tulinius H, Watanabe Y, Ozasa K, Kurata JH, Hansen S, Melby KK, Aase S, Jellum E, Vollset SE, Siman JH, Forsgren A, Berglund G, Floren CH, Lin JT, Chen CJ, Wald NJ, Parsonnet J, Friedman GD, Blaser MJ, Nomura A, Stemmermann GN (2001) Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut 49:347–353CrossRef
20.
Huang JQ, Zheng GF, Sumanac K, Irvine EJ, Hunt RH (2003) Meta-analysis of the relationship between cagA seropositivity and gastric cancer. Gastroenterology 125:1636–1644CrossRefPubMed
21.
22.
Limburg P, Qiao Y, Mark S et al (2001) Helicobacter pylori seropositivity and subsite-specific gastric cancer risks in Linxian, China. J Natl Cancer Inst 93:226–233CrossRefPubMed
23.
Chow WH, Blaser MJ, Blot WJ et al (1998) An inverse relation between cagA + strains of Helicobacter pylori infection and risk of esophageal and gastric cardia adenocarcinoma. Cancer Res 58:588–590PubMed
24.
Brenner H, Arndt V, Stegmaier C, Ziegler H, Rothenbacher D (2004) Is Helicobacter pylori infection a necessary condition for noncardia gastric cancer? Am J Epidemiol 159:252–258CrossRefPubMed
25.
Nomura AM, Kolonel LN, Miki K et al (2005) Helicobacter pylori, pepsinogen, and gastric adenocarcinoma in Hawaii. J Infect Dis 191:2075–2081CrossRefPubMed
26.
Kamangar F, Dawsey SM, Blaser MJ et al (2006) Opposing risks of gastric cardia and noncardia gastric adenocarcinomas associated with Helicobacter pylori seropositivity. J Natl Cancer Inst 98:1445–1452CrossRefPubMed
27.
Talley NJ, Zinsmeister AR, Weaver A et al (1991) Gastric adenocarcinoma and Helicobacter pylori infection. J Natl Cancer Inst 83:1734–1739CrossRefPubMed
28.
Shibata T, Imoto I, Ohuchi Y et al (1996) Helicobacter pylori infection in patients with gastric carcinoma in biopsy and surgical resection specimens. Cancer 77:1044–1049CrossRefPubMed
29.
Fukuda H, Saito D, Hayashi S et al (1995) Helicobacter pylori infection, serum pepsinogen level and gastric cancer: a case–control study in Japan. Jpn J Cancer Res 86:64–71PubMed
30.
Kim HY, Cho BD, Chang WK et al (1997) Helicobacter pylori infection and the risk of gastric cancer among the Korean population. J Gastroenterol Hepatol 12:100–103CrossRefPubMed
31.
Kamangar F, Qiao YL, Blaser MJ et al (2007) Helicobacter pylori and oesophageal and gastric cancers in a prospective study in China. Br J Cancer 96:172–176CrossRefPubMed
32.
Lunet N (2006) Gastric cancer frequency and trends. Arq Med 20:79–85
33.
Wu AH, Crabtree JE, Bernstein L et al (2003) Role of Helicobacter pylori CagA + strains and risk of adenocarcinoma of the stomach and esophagus. Int J Cancer 103:815–821CrossRefPubMed
34.
Shen J, Wang RT, Wang LW, Xu YC, Wang XR (2004) A novel genetic polymorphism of inducible nitric oxide synthase is associated with an increased risk of gastric cancer. World J Gastroenterol 10:3278–3283PubMed
35.
Kokkola A, Louhimo J, Puolakkainen P, Alfthan H, Haglund C, Rautelin H (2005) Helicobacter pylori infection and low serum pepsinogen I level as risk factors for gastric carcinoma. World J Gastroenterol 11:1032–1036PubMed
36.
Held M, Engstrand L, Hansson LE, Bergstrom R, Wadstrom T, Nyren O (2004) Is the association between Helicobacter pylori and gastric cancer confined to CagA-positive strains? Helicobacter 9:271–277CrossRefPubMed
37.
Queiroz DM, Mendes EN, Rocha GA et al (1998) CagA-positive Helicobacter pylori and risk for developing gastric carcinoma in Brazil. Int J Cancer 78:135–139CrossRefPubMed
38.
Yamaoka Y, Kodama T, Kashima K, Graham DY (1999) Antibody against Helicobacter pylori CagA and VacA and the risk for gastric cancer. J Clin Pathol 52:215–218CrossRefPubMed
39.
Mitchell H, English DR, Elliott F et al (2008) Immunoblotting using multiple antigens is essential to demonstrate the true risk of Helicobacter pylori infection for gastric cancer. Aliment Pharmacol Ther 28:903–910PubMed
40.
Lin JT, Wang JT, Wang TH, Wu MS, Lee TK, Chen CJ (1993) Helicobacter pylori infection in a randomly selected population, healthy volunteers, and patients with gastric ulcer and gastric adenocarcinoma. A seroprevalence study in Taiwan. Scand J Gastroenterol 28:1067–1072CrossRefPubMed
41.
Lee BM, Jang JJ, Kim JS et al (1998) Association of Helicobacter pylori infection with gastric adenocarcinoma. Jpn J Cancer Res 89:597–603PubMed
42.
Kikuchi S, Crabtree JE, Forman D, Kurosawa M (1999) Association between infections with CagA-positive or -negative strains of Helicobacter pylori and risk for gastric cancer in young adults. Research Group on Prevention of Gastric Carcinoma Among Young Adults. Am J Gastroenterol 94:3455–3459CrossRefPubMed
43.
Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558CrossRefPubMed
44.
GLOBOCAN 2002 (2004) Cancer incidence, mortality and prevalence worlwide [database on the Internet]. IARC Press, Lyon
45.
Society AC (2004) Hawaii cancer facts & figures 2003–2004
46.
Crew KD, Neugut AI (2006) Epidemiology of gastric cancer. World J Gastroenterol 12:354–362PubMed
47.
Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, Boyle P (eds) (2007) Cancer incidence in five continents, vol IX. IARC Scientific Publications No. 160. IARC, Lyon
48.
Parsonnet J, Friedman GD, Vandersteen DP et al (1991) Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 325:1127–1131CrossRefPubMed
49.
Lin JT, Wang JT, Wang TH, Wu MS, Chen CJ (1993) Helicobacter pylori infection in early and advanced gastric adenocarcinoma: a seroprevalence study in 143 Taiwanese patients. Hepatogastroenterology 40:596–599PubMed
50.
Hansson LE, Engstrand L, Nyren O et al (1993) Helicobacter pylori infection: independent risk indicator of gastric adenocarcinoma. Gastroenterology 105:1098–1103PubMed
51.
Kikuchi S, Wada O, Nakajima T et al (1995) Serum anti-Helicobacter pylori antibody and gastric carcinoma among young adults. Research Group on Prevention of Gastric Carcinoma among Young Adults. Cancer 75:2789–2793CrossRefPubMed
52.
Webb PM, Yu MC, Forman D et al (1996) An apparent lack of association between Helicobacter pylori infection and risk of gastric cancer in China. Int J Cancer 67:603–607CrossRefPubMed
53.
Siman JH, Forsgren A, Berglund G, Floren CH (1997) Association between Helicobacter pylori and gastric carcinoma in the city of Malmo, Sweden. A prospective study. Scand J Gastroenterol 32:1215–1221CrossRefPubMed
54.
Brenner H, Arndt V, Sturmer T, Stegmaier C, Ziegler H, Dhom G (2000) Individual and joint contribution of family history and Helicobacter pylori infection to the risk of gastric carcinoma. Cancer 88:274–279CrossRefPubMed
55.
Brenner H, Arndt V, Bode G, Stegmaier C, Ziegler H, Stumer T (2002) Risk of gastric cancer among smokers infected with Helicobacter pylori. Int J Cancer 98:446–449CrossRefPubMed
56.
Enroth H, Kraaz W, Rohan T, Nyren O, Engstrand L (2002) Does the method of Helicobacter pylori detection influence the association with gastric cancer risk? Scand J Gastroenterol 37:884–890CrossRefPubMed
57.
Gonzalez CA, Jakszyn P, Pera G et al (2006) Meat intake and risk of stomach and esophageal adenocarcinoma within the European Prospective Investigation into Cancer and Nutrition (EPIC). J Natl Cancer Inst 98:345–354CrossRefPubMed
58.
Gonzalez CA, Pera G, Agudo A et al (2006) Fruit and vegetable intake and the risk of stomach and oesophagus adenocarcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST). Int J Cancer 118:2559–2566CrossRefPubMed
59.
Hansen S, Vollset SE, Derakhshan MH et al (2007) Two distinct aetiologies of cardia cancer; evidence from premorbid serological markers of gastric atrophy and Helicobacter pylori status. Gut 56:918–925CrossRefPubMed
60.
Ren JS, Qiao YL (2008) Helicobacter pylori infection and gastric cardia cancer: a nested case–control study. Zhonghua Zhong Liu Za Zhi 30:428–431PubMed
61.
Estevens J, Fidalgo P, Tendeiro T et al (1993) Anti-Helicobacter pylori antibodies prevalence and gastric adenocarcinoma in Portugal: report of a case–control study. Eur J Cancer Prev 2:377–380CrossRefPubMed
62.
Blaser MJ, Perez-Perez GI, Kleanthous H et al (1995) Infection with Helicobacter pylori strains possessing cagA is associated with an increased risk of developing adenocarcinoma of the stomach. Cancer Res 55:2111–2115PubMed
63.
Aromaa A, Kosunen TU, Knekt P et al (1996) Circulating anti-Helicobacter pylori immunoglobulin A antibodies and low serum pepsinogen I level are associated with increased risk of gastric cancer. Am J Epidemiol 144:142–149PubMed
64.
Martin-de-Argila C, Boixeda D, Redondo C et al (1997) Relation between histologic subtypes and location of gastric cancer and Helicobacter pylori. Scand J Gastroenterol 32:303–307CrossRefPubMed
65.
Erkisi M, Colakoglu S, Koksal F et al (1997) Relationship of Helicobacter pylori infection to several malignant and non-malignant gastrointestinal diseases. J Exp Clin Cancer Res 16:289–293PubMed
66.
Whiting JL, Hallissey MT, Fielding JW, Dunn J (1998) Screening for gastric cancer by Helicobacter pylori serology: a retrospective study. Br J Surg 85:408–411CrossRefPubMed
67.
Louw JA, Kidd MS, Kummer AF, Taylor K, Kotze U, Hanslo D (2001) The relationship between Helicobacter pylori infection, the virulence genotypes of the infecting strain and gastric cancer in the African setting. Helicobacter 6:268–273CrossRefPubMed
68.
Watabe H, Mitsushima T, Yamaji Y et al (2005) Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study. Gut 54:764–768CrossRefPubMed
69.
Suzuki G, Cullings H, Fujiwara S et al (2007) Low-positive antibody titer against Helicobacter pylori cytotoxin-associated gene A (CagA) may predict future gastric cancer better than simple seropositivity against H. pylori CagA or against H. pylori. Cancer Epidemiol Biomarkers Prev 16:1224–1228CrossRefPubMed
70.
Palli D, Masala G, Del Giudice G et al (2007) CagA + Helicobacter pylori infection and gastric cancer risk in the EPIC-EURGAST study. Int J Cancer 120:859–867CrossRefPubMed
71.
Knekt P, Teppo L, Aromaa A, Rissanen H, Kosunen TU (2006) Helicobacter pylori IgA and IgG antibodies, serum pepsinogen I and the risk of gastric cancer: changes in the risk with extended follow-up period. Int J Cancer 119:702–705CrossRefPubMed
72.
Ekstrom AM, Held M, Hansson LE, Engstrand L, Nyren O (2001) Helicobacter pylori in gastric cancer established by CagA immunoblot as a marker of past infection. Gastroenterology 121:784–791CrossRefPubMed
73.
Siman JH, Engstrand L, Berglund G, Forsgren A, Floren CH (2007) Helicobacter pylori and CagA seropositivity and its association with gastric and oesophageal carcinoma. Scand J Gastroenterol 42:933–940CrossRefPubMed
74.
Rudi J, Muller M, von Herbay A et al (1995) Lack of association of Helicobacter pylori seroprevalence and gastric cancer in a population with low gastric cancer incidence. Scand J Gastroenterol 30:958–963CrossRefPubMed
75.
Hansen S, Melby KK, Aase S, Jellum E, Vollset SE (1999) Helicobacter pylori infection and risk of cardia cancer and non-cardia gastric cancer. A nested case–control study. Scand J Gastroenterol 34:353–360CrossRefPubMed
76.
Ye W, Held M, Lagergren J et al (2004) Helicobacter pylori infection and gastric atrophy: risk of adenocarcinoma and squamous-cell carcinoma of the esophagus and adenocarcinoma of the gastric cardia. J Natl Cancer Inst 96:388–396CrossRefPubMed
77.
Yamagata H, Kiyohara Y, Aoyagi K et al (2000) Impact of Helicobacter pylori infection on gastric cancer incidence in a general Japanese population: the Hisayama study. Arch Intern Med 160:1962–1968CrossRefPubMed
78.
Kato M, Asaka M, Shimizu Y, Nobuta A, Takeda H, Sugiyama T (2004) Relationship between Helicobacter pylori infection and the prevalence, site and histological type of gastric cancer. Aliment Pharmacol Ther 20(Suppl 1):85–89CrossRefPubMed
79.
Shin A, Shin HR, Kang D, Park SK, Kim CS, Yoo KY (2005) A nested case–control study of the association of Helicobacter pylori infection with gastric adenocarcinoma in Korea. Br J Cancer 92:1273–1275CrossRefPubMed
80.
Derakhshan MH, Malekzadeh R, Watabe H et al (2008) Combination of gastric atrophy, reflux symptoms and histological subtype indicates two distinct aetiologies of gastric cardia cancer. Gut 57:298–305CrossRefPubMed
81.
Sasazuki S, Inoue M, Iwasaki M et al (2006) Effect of Helicobacter pylori infection combined with CagA and pepsinogen status on gastric cancer development among Japanese men and women: a nested case–control study. Cancer Epidemiol Biomarkers Prev 15:1341–1347CrossRefPubMed
82.
Komoto K, Haruma K, Kamada T et al (1998) Helicobacter pylori infection and gastric neoplasia: correlations with histological gastritis and tumor histology. Am J Gastroenterol 93:1271–1276CrossRefPubMed
83.
Yuan JM, Yu MC, Xu WW, Cockburn M, Gao YT, Ross RK (1999) Helicobacter pylori infection and risk of gastric cancer in Shanghai, China: updated results based upon a locally developed and validated assay and further follow-up of the cohort. Cancer Epidemiol Biomarkers Prev 8:621–624PubMed
84.
Yang KC, Chu A, Liao CS, Lin YM, Wang GM (2006) Evaluation of the role of H. pylori infection in pathogenesis of gastric cancer by immunoblot assay. World J Gastroenterol 12:7029–7032PubMed
85.
Parsonnet J, Samloff IM, Nelson LM, Orentreich N, Vogelman JH, Friedman GD (1993) Helicobacter pylori, pepsinogen, and risk for gastric adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2:461–466PubMed
86.
Enroth H, Kraaz W, Engstrand L, Nyren O, Rohan T (2000) Helicobacter pylori strain types and risk of gastric cancer: a case–control study. Cancer Epidemiol Biomarkers Prev 9:981–985PubMed
87.
Zhang ZF, Kurtz RC, Klimstra DS et al (1999) Helicobacter pylori infection on the risk of stomach cancer and chronic atrophic gastritis. Cancer Detect Prev 23:357–367CrossRefPubMed
88.
Lochhead P, El-Omar EM (2007) Helicobacter pylori infection and gastric cancer. Best Pract Res Clin Gastroenterol 21:281–297CrossRefPubMed
89.
Marsman WA, Tytgat GN, ten Kate FJ, van Lanschot JJ (2005) Differences and similarities of adenocarcinomas of the esophagus and esophagogastric junction. J Surg Oncol 92:160–168CrossRefPubMed
90.
Lunet N, Azevedo A (2009) On the comparability of population-based and hospital-based case–control studies. Gac Sanit 23:564; author reply 565
91.
Peleteiro B, Lunet N, Barros R, La Vecchia C, Barros H (2010) Factors contributing to the underestimation of Helicobacter pylori-associated gastric cancer risk in a high-prevalence population. Cancer Causes Control 21:1257–1264CrossRefPubMed
Metadata
Title
Helicobacter pylori infection and gastric cardia cancer: systematic review and meta-analysis
Authors
Marlene Cavaleiro-Pinto
Bárbara Peleteiro
Nuno Lunet
Henrique Barros
Publication date
01-03-2011
Publisher
Springer Netherlands
Published in
Cancer Causes & Control / Issue 3/2011
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-010-9707-2

Other articles of this Issue 3/2011

Cancer Causes & Control 3/2011 Go to the issue

Original paper

Repetitive element hypomethylation in blood leukocyte DNA and cancer incidence, prevalence, and mortality in elderly individuals: the Normative Aging Study

Original paper

Chromosome 15q24-25.1 variants, diet, and lung cancer susceptibility in cigarette smokers

Original paper

Reproductive history and risk of three breast cancer subtypes defined by three biomarkers

Original paper

Physical activity, additional breast cancer events, and mortality among early-stage breast cancer survivors: findings from the WHEL Study

Original paper

Bladder cancer mortality trends and patterns in Córdoba, Argentina (1986–2006)

Original paper

Cohorts and consortia conference: a summary report (Banff, Canada, June 17–19, 2009)
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits